• Home
  • Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Author List
Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/420600776
Publication Year
2023
Publication Title
Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng. Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy. Journal of Clinical Oncology. 2023 Feb 1; 41(4_suppl):tps630-tps630.